GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Retail - Cyclical » Innovative Pharmaceutical Biotech Ltd (HKSE:00399) » Definitions » ROC %

Innovative Pharmaceutical Biotech (HKSE:00399) ROC % : -0.73% (As of Sep. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Innovative Pharmaceutical Biotech ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Innovative Pharmaceutical Biotech's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was -0.73%.

As of today (2025-04-01), Innovative Pharmaceutical Biotech's WACC % is 17.03%. Innovative Pharmaceutical Biotech's ROC % is -0.77% (calculated using TTM income statement data). Innovative Pharmaceutical Biotech earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Innovative Pharmaceutical Biotech ROC % Historical Data

The historical data trend for Innovative Pharmaceutical Biotech's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovative Pharmaceutical Biotech ROC % Chart

Innovative Pharmaceutical Biotech Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.21 -1.22 -1.37 -1.06 -0.64

Innovative Pharmaceutical Biotech Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.86 -1.13 -0.60 -0.84 -0.73

Innovative Pharmaceutical Biotech ROC % Calculation

Innovative Pharmaceutical Biotech's annualized Return on Capital (ROC %) for the fiscal year that ended in Mar. 2024 is calculated as:

ROC % (A: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Mar. 2023 ) + Invested Capital (A: Mar. 2024 ))/ count )
=-13.434 * ( 1 - 0% )/( (2471.424 + 1717.209)/ 2 )
=-13.434/2094.3165
=-0.64 %

where

Innovative Pharmaceutical Biotech's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-14.17 * ( 1 - 0% )/( (1717.209 + 2177.073)/ 2 )
=-14.17/1947.141
=-0.73 %

where

Note: The Operating Income data used here is two times the semi-annual (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovative Pharmaceutical Biotech  (HKSE:00399) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Innovative Pharmaceutical Biotech's WACC % is 17.03%. Innovative Pharmaceutical Biotech's ROC % is -0.77% (calculated using TTM income statement data). Innovative Pharmaceutical Biotech earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Innovative Pharmaceutical Biotech ROC % Related Terms

Thank you for viewing the detailed overview of Innovative Pharmaceutical Biotech's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovative Pharmaceutical Biotech Business Description

Traded in Other Exchanges
N/A
Address
145 Hennessy Road, Unit No. 2002, 20th Floor, On Hong Commercial Building, Wan Chai, Hong Kong, HKG
Innovative Pharmaceutical Biotech Ltd is a Hong Kong-based investment holding company principally engaged in pharmaceuticals and biotechnology businesses. The company has two operating segments; Trading of beauty products in Hong Kong and Research, development, and commercialisation of the oral insulin product. The company generates almost all of its revenue from Hong Kong.
Executives
Mao Yumin 2101 Beneficial owner
Chau Yiu Ting 2101 Beneficial owner
Extrawell Pharmaceutical Holdings Limited
Mao Yumin 2101 Beneficial owner
Chau Yiu Ting 2101 Beneficial owner

Innovative Pharmaceutical Biotech Headlines

No Headlines